Figure 2.

Forest plot of eGFR change from baseline to week 100 by subgroups. Forest plot summarizing mean±95% confidence interval difference between bardoxolone methyl (bard) and placebo groups in the change from baseline in eGFR at 100 weeks for subgroups on the basis of baseline characteristics at randomization. Mean difference between treatment groups at 100 weeks was analyzed for each subgroup using mixed model repeated measures and included all available eGFR values collected through week 100 for the intention-to-treat (ITT) population, with the number of patients contributing to the analysis for each subgroup noted in the figure and the P value indicating the difference between subgroups. ACE, angiotensin-converting enzyme; N, no; US, United States; XLAS, X-linked Alport syndrome; Y, yes.